European drugs regulator to review Wegovy, Ozempic following reports of suicidal thoughts
Publishing timestamp: 2023-07-10 11:31:55
Summary
The European Medicines Agency (EMA) has announced a review into drugs used to treat obesity and diabetes, specifically semaglutide and liraglutide-containing medicines, after reports of patients experiencing thoughts of suicide or self-harm. The review was prompted by three case reports from the Icelandic Medicines Agency. Novo Nordisk, the manufacturer of these drugs, stated that patient safety is their top priority and that there is no demonstrated causal association between their products and these adverse events. The EMA will consider extending the review to include other medicines of the same class.
Sentiment: MIXED
Tickers: NOVO.B-DK,
Keywords: novo nordisk a/s, business news, pharmaceuticals, denmark, biotech and pharmaceuticals, eu,